Intercept Pharmaceuticals Inc (ICPT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jerome B. Durso
Employees:
440
450 W. 15TH STREET, SUITE 505, NEW YORK, NY 10011
646-747-1000

Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept also has a license agreement with Aralez Pharmaceuticals Canada to develop and commercialize bezafibrate.

Data derived from most recent annual or quarterly report
Market Cap 447.12 Million Shares Outstanding41.67 Million Avg 30-day Volume 1.881 Million
P/E Ratio2.704 Dividend Yield0.0 EPS6.37
Price to Revenue1.9001 Debt to Equity4.9571 EBITDA-64.874 Million
Price to Book Value8.3297 Operating Margin-24.9285 Enterprise Value457.453 Million
Current Ratio2.368 EPS Growth3.857 Quick Ratio2.232
1 Yr BETA 1.1625 52-week High/Low 21.86 / 8.82 Profit Margin70.2715
Operating Cash Flow Growth-790.7187 Altman Z-Score-4.4157 Free Cash Flow to Firm -76.403 Million
Earnings Report2023-08-03

Are you looking for this stock instead?

View SEC Filings from ICPT instead.

View recent insider trading info

Intercept Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ICPT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ICPT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-25 by BENATTI LUCA
  • 4: filed on 2023-05-25 by SBLENDORIO GLENN
  • 4: filed on 2023-05-25 by GOTTESDIENER KEITH MICHAEL
  • 4: filed on 2023-05-25 by FUNDARO PAOLO
  • 4: filed on 2023-05-25 by SANTINI GINO
  • 4: filed on 2023-05-25 by ROSA-BJORKESON DAGMAR
  • 4: filed on 2023-05-25 by MILLER-RICH NANCY
  • 4: filed on 2023-05-03 by FREEDBERG JARED
  • 4: filed on 2023-03-23 by SAIK ANDREW
  • 4: filed on 2023-03-16 by BERREY M MICHELLE

    • Events (8k)

  • 8-K: filed on 2023-05-25:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-18:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-21:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-25:
    Item 8.01: Other Events
  • 8-K: filed on 2023-01-19:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BRADBURY DANIEL

    • Director
    		 39,471 2023-05-24 1

    AKKARAJU SRINIVAS

    • Director
    		 686,686 2023-05-24 1

    SANTINI GINO

    • Director
    		 31,756 2023-05-24 1

    SBLENDORIO GLENN

    • Director
    		 31,558 2023-05-24 1

    FUNDARO PAOLO

    • Director
    		 43,905 2023-05-24 1

    BENATTI LUCA

    • Director
    		 33,598 2023-05-24 1

    GOTTESDIENER KEITH MICHAEL

    • Director
    		 32,830 2023-05-24 1

    ROSA-BJORKESON DAGMAR

    • Director
    		 26,391 2023-05-24 1

    MILLER-RICH NANCY

    • Director
    		 30,415 2023-05-24 1

    FREEDBERG JARED GENERAL COUNSEL

    • Officer
    		 57,985 2023-05-01 6

    SAIK ANDREW EVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 70,081 2023-03-21 6

    BERREY M MICHELLE PRESIDENT, R&D & CMO

    • Officer
    		 82,631 2023-03-14 6

    RICHARDSON LINDA M EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 43,291 2023-02-14 5

    DURSO JEROME BENEDICT PRESIDENT & CEO

    • Officer
    • Director
    		 237,340 2023-01-27 2

    FORD DAVID A CHIEF HUMAN RESOURCES OFFICER

    • Officer
    		 52,438 2023-01-27 2

    VENEZIA ROCCO CHIEF ACCOUNTING OFFICER

    • Officer
    		 41,451 2023-01-27 3

    BALL BRYAN CHIEF QUAL. OFFICER & SVP OPS.

    • Officer
    		 25,178 2022-07-11 1

    CAWKWELL GAIL SVP, MED AFFAIRS, SAFETY & PV

    • Officer
    		 35,740 2022-02-12 0

    DEFRANCESCO LISA SVP, IR & CORP. AFFAIRS

    • Officer
    		 10,308 2021-12-31 0

    PRUZANSKI MARK

    • Director
    		 618,894 2021-11-30 0

    WEYER CHRISTIAN EVP, RESEARCH & DEVELOPMENT

    • Officer
    		 27,341 2021-04-01 0

    KAPADIA SANDIP CFO AND TREASURER

    • Officer
    		 40,964 2021-01-22 0

    CAMPAGNA JASON CHIEF MEDICAL OFFICER

    • Officer
    		 20,531 2021-01-22 0

    KIM RICHARD J PRESIDENT US COMM & STRAT MKTG

    • Officer
    		 19,770 2020-12-31 0

    SULLIVAN RYAN T GENERAL COUNSEL AND SECRETARY

    • Officer
    		 24,708 2020-11-13 0

    GENEXTRA S.P.A.

    • 10% Owner
    		 4,000,000 2020-08-13 0

    MICHELI FRANCESCO

    • 10% Owner
    		 4,000,000 2020-08-13 0

    BRIGHT LISA PRESIDENT, INTERNATIONAL

    • Officer
    		 22,012 2020-07-01 0

    WELCH DANIEL G

    • Director
    		 8,060 2020-05-28 0

    SHAPIRO DAVID CHIEF MEDICAL OFFICER

    • Officer
    		 39,499 2019-05-01 0

    BRIGHT LISA PRESIDENT, INTERNATIONAL

    BRIGHT LISA PRESIDENT, INTERNATIONAL

    • Officer
    		 18,807 2019-01-07 0

    MCMINN RACHEL CHIEF STRATEGY OFFICER

    • Officer
    		 16,875 2017-10-02 0

    DUNCAN BARBARA GAYLE CHIEF ACCOUNTING OFFICER

    • Officer
    		 30,661 2016-10-03 0

    ADORINI LUCIANO SEE REMARKS

    • Officer
    		 No longer subject to file 2016-02-01 0

    SILVERSTEIN JONATHAN

    • Director
    		 1,121,583 2015-11-24 0

    VEITINGER KLAUS R DR

    • Director
    		 2,816 2015-11-24 0

    WILLIAMS NICOLE

    • Director
    		 1,936 2015-11-20 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP IV LLC

    ISALY SAMUEL D

    • Director
    		 1,120,609 2015-07-17 0

    REGAN DANIEL PAUL CHIEF COMMERCIAL OFFICER

    • Officer
    		 1,264 2015-01-30 0

    PATEL SANJ K

    • Director
    		 452 2014-07-17 0

    TALLARIGO LORENZO

    • Director
    		 0 2014-07-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SANTINI GINO - Director

    		2023-05-25 20:39:30 -0400 2023-05-24 A 8,111 a 31,756 direct 4.9708 4.9708 2 0.0 1

    BENATTI LUCA - Director

    		2023-05-25 20:40:49 -0400 2023-05-24 A 12,547 a 12,547 direct

    BENATTI LUCA - Director

    		2023-05-25 20:40:49 -0400 2023-05-24 A 8,111 a 33,598 direct 4.9708 4.9708 2 0.0 1

    SBLENDORIO GLENN - Director

    		2023-05-25 20:40:31 -0400 2023-05-24 A 12,547 a 12,547 direct

    SBLENDORIO GLENN - Director

    		2023-05-25 20:40:31 -0400 2023-05-24 A 8,111 a 31,558 direct 4.9708 4.9708 2 0.0 1

    FUNDARO PAOLO - Director

    		2023-05-25 20:39:52 -0400 2023-05-24 A 12,547 a 12,547 direct

    FUNDARO PAOLO - Director

    		2023-05-25 20:39:52 -0400 2023-05-24 A 8,111 a 43,905 direct 4.9708 4.9708 2 0.0 1

    GOTTESDIENER KEITH MICHAEL - Director

    		2023-05-25 20:40:13 -0400 2023-05-24 A 12,547 a 12,547 direct

    GOTTESDIENER KEITH MICHAEL - Director

    		2023-05-25 20:40:13 -0400 2023-05-24 A 8,111 a 32,830 direct 4.9708 4.9708 2 0.0 1

    SANTINI GINO - Director

    		2023-05-25 20:39:30 -0400 2023-05-24 A 12,547 a 12,547 direct

    ROSA-BJORKESON DAGMAR - Director

    		2023-05-25 20:39:02 -0400 2023-05-24 A 12,547 a 12,547 direct

    ROSA-BJORKESON DAGMAR - Director

    		2023-05-25 20:39:02 -0400 2023-05-24 A 8,111 a 26,391 direct 4.9708 4.9708 2 0.0 1

    MILLER-RICH NANCY - Director

    		2023-05-25 20:38:05 -0400 2023-05-24 A 12,547 a 12,547 direct

    MILLER-RICH NANCY - Director

    		2023-05-25 20:38:05 -0400 2023-05-24 A 8,111 a 30,415 direct 4.9708 4.9708 2 0.0 1

    BRADBURY DANIEL - Director

    		2023-05-25 20:37:35 -0400 2023-05-24 A 12,547 a 12,547 direct

    BRADBURY DANIEL - Director

    		2023-05-25 20:37:35 -0400 2023-05-24 A 8,111 a 31,659 direct 4.9708 4.9708 2 0.0 1

    AKKARAJU SRINIVAS - Director

    		2023-05-25 20:37:15 -0400 2023-05-24 A 12,547 a 12,547 direct

    AKKARAJU SRINIVAS - Director

    		2023-05-25 20:37:15 -0400 2023-05-24 A 8,111 a 45,998 direct 4.9708 4.9708 2 0.0 1

    FREEDBERG JARED - Officer GENERAL COUNSEL

    		2023-05-03 16:01:00 -0400 2023-05-01 F 771 $17.07 d 57,985 direct 1.1264 -2.2528 1.1264 2 -2.2528 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 22:15:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 21:45:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 21:15:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 20:45:03 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 20:15:05 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 19:45:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 19:15:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 18:45:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 18:15:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 17:45:03 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 17:15:04 UTC 4.6519 0.4081 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 16:45:03 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 16:15:04 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 15:45:04 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 15:15:03 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 14:45:04 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 14:15:03 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 13:45:03 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 13:15:04 UTC 4.6608 0.4092 800000
    INTERCEPT PHARMACEUTICALS IN ICPT 2023-06-02 12:45:03 UTC 4.6608 0.4092 800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AQR Funds- AQR Multi-Strategy Alternative Fund ICPT -9.0 shares, $-373.14 2020-09-30 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund ICPT -1113.0 shares, $-25688.04 2021-03-31 N-PORT
    Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund ICPT -44947.0 shares, $-907030.46 2023-02-28 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments